慢性乙型肝炎患者外周血T淋巴细胞与肝功能及HBV DNA的关系

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎患者外周血T淋巴细胞亚群与肝功能及HBV DNA之间的关联。方法纳入2022年3月至2024年3月在安徽省临泉县人民医院诊断的70例慢性乙型肝炎患者为观察组,基于HBV DNA载量将其划分为高载量组(36例)和低载量组(34例),以及健康对照组(n=40)。测定所有参与者的外周血T淋巴细胞亚群,记录肝功能指标和HBV DNA。运用Pearson相关性分析探讨外周血T淋巴细胞与肝功能指标及HBV DNA的相关性。结果高载量组患者的CD4⁺水平(42.17±5.40%)和Alb水平(31.21±4.13 g/L)低于低载量组(CD4⁺: 45.08±6.13%,Alb: 36.32±5.26 g/L)和对照组(CD4⁺: 48.50±5.29%,Alb: 45.83±6.15 g/L)。高载量组患者的CD8⁺水平(29.50±3.30%)、CD4⁺CD25⁺水平(35.09±6.12%)、ALT水平(62.86±9.25 U/L)、AST水平(59.35±6.08 U/L)、TBil水平(37.19±3.27 μmol/L)均高于低载量组(CD8⁺: 23.82±3.76%,CD4⁺CD25⁺: 30.57±5.41%,ALT: 37.52±5.30 U/L, AST: 35.72±5.17 U/L, TBil: 19.61±4.43 μmol/L)和对照组(CD8⁺: 21.26±3.16%,CD4⁺CD25⁺: 26.75±3.34%,ALT: 18.35±3.11 U/L, AST: 16.22±3.23 U/L, TBil: 9.21±2.65 μmol/L)。高载量组患者的HBV DNA水平(7.48±2.09 lgIU/mL)高于低载量组(5.53±1.11 lgIU/mL)(P<0.05)。Pearson相关性分析显示,患者CD4⁺水平与ALT、AST、TBil、HBV DNA呈显著负相关,与Alb呈显著正相关;CD8⁺、CD4⁺CD25⁺与ALT、AST、TBil、HBV DNA呈显著正相关,与Alb呈显著负相关(P<0.05)。结论慢性乙型肝炎患者外周血T淋巴细胞亚群与肝功能指标及HBV DNA含量密切相关,可作为评估疾病进展和预后的重要免疫学指标。

关键词: 慢性乙型肝炎, T淋巴细胞亚群, 肝功能, HBV DNA, 相关性

Abstract: Objective To explore the correlation between peripheral blood T lymphocyte subsets and liver function, as well as HBV DNA in patients with chronic hepatitis B (CHB). Methods Between March 2022 and March 2024, 70 patients with a diagnosis of CHB were included in this study from the People's Hospital of Linquan County, Anhui Province. Based on HBV DNA levels, patients were categorized into a high viral load group (36 cases) and a low viral load group (34 cases), alongside a healthy control group (n=40). Peripheral blood T lymphocyte subsets were measured for all participants, and liver function indicators along with HBV DNA were recorded. Pearson correlation analysis was employed to examine the relationship between peripheral blood T lymphocytes and liver function indicators, as well as HBV DNA. Results Patients in the high-load group exhibited the lower levels of CD4⁺ (42.17±5.40%) and Albumin (Alb, 31.21±4.13 g/L) compared to those in the low-load group (CD4⁺: 45.08±6.13%, Alb: 36.32±5.26 g/L) and the control group (CD4⁺: 48.50±5.29%, Alb:45.83±6.15 g/L). Furthermore, the levels of CD8⁺ (29.50±3.30%), CD4⁺CD25⁺ (35.09±6.12%), Alanine Aminotransferase (ALT, 62.86±9.25 U/L), Aspartate Aminotransferase (AST, 59.35±6.08 U/L), and Total Bilirubin (TBil, 37.19±3.27 μmol/L) were higher in the high-load group than in the low-load group (CD8⁺: 23.82±3.76%, CD4⁺CD25⁺: 30.57±5.41%, ALT: 37.52±5.30 U/L, AST: 35.72±5.17 U/L, TBil: 19.61±4.43 μmol/L) and the control group (CD8⁺: 21.26±3.16%, CD4⁺CD25⁺: 26.75±3.34%, ALT: 18.35±3.11 U/L, AST: 16.22±3.23 U/L, TBil: 9.21±2.65 μmol/L). The HBV DNA level (7.48±2.09 lgIU/mL) in the high-load group was higher than that in the low-load group (5.53±1.11 lgIU/mL) (P<0.05). Pearson correlation analysis revealed that CD4⁺ levels were significantly negatively correlated with ALT, AST, TBil, and HBV DNA, and positively correlated with Alb. The CD8⁺ and CD4⁺CD25⁺ levels were significantly positively correlated with ALT, AST, TBil, and HBV DNA, and negatively correlated with Alb (P<0.05). Conclusion The subsets of peripheral blood T lymphocytes in patients with CHB are closely related to liver function indicators and HBV DNA levels, serving as important immunological markers for assessing disease progression and prognosis.

Key words: Chronic hepatitis B, T lymphocyte subsets, Liver function, HBV DNA, Correlation

王倩, 高翠花. 慢性乙型肝炎患者外周血T淋巴细胞与肝功能及HBV DNA的关系[J]. 肝脏, 2025, 30(5): 655-658.

WANG Qian, GAO Cui-hua. The relationship between peripheral blood T lymphocytes and liver function, as well as HBV DNA, in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2025, 30(5): 655-658.

/ 推荐

参考文献

[1] 张晓晶, 武瑞, 黄伟, 等. 慢性乙型肝炎不同自然病程HBV RNA的动态变化及与HBsAg、HBV DNA的相关性研究[J]. 中国卫生检验杂志,2022,32(15):1832-1835.
[2] Yang J, Lu H, Chen B, et al. Profiling of peripheral TRBV and CD4⁺ CD25⁺ Treg in CHB patients with HBeAg SC during TDF treatment[J]. J Immunol Res, 2023, 2023.
[3] Zhu L, Li J, Xu J, et al. Significance of T-Cell subsets for clinical response to peginterferon Alfa-2a therapy in HBeAg-positive chronic hepatitis B patients[J]. Int J Gen Med, 2022: 4441-4451.
[4] 白瑞, 鲍中英, 王硕, 等. 乙型肝炎肝硬化患者外周血IL-6水平与肝功能、HBV DNA载量及感染幽门螺杆菌的相关性研究[J]. 海军医学杂志,2022,43(5):517-521.
[5] 贾春锋, 高旋, 徐倩, 等. 不同HBsAg水平的慢性乙型肝炎患者血清HIF-1α、ApoE和TGF-β1水平变化及其临床意义探讨[J]. 实用肝脏病杂志,2023,26(1):140-142.
[6] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志,2019,35(12):2648-2669.
[7] 骆乐, 薛华, 罗兰云, 等. 抗病毒治疗对乙型肝炎相关性肝癌术后肝内复发患者生存状况的影响[J]. 中国现代医学杂志,2018,28(10):89-93.
[8] Campbell K. Hepatitis B and the liver cancer endgame[J]. Nature, 2022, 603(7903): S64-S65.
[9] Yao C, Hu Z, Yuan R, et al. CD32 expression by CD4⁺ T and CD8⁺ T lymphocytes is increased in patients with chronic hepatitis B virus infection[J]. Viral Immunol, 2023,36(5):351-359.
[10] 陈淑湘, 刘新, 娄金丽. 临床中隐匿性HBV感染的病毒血清标志物和T淋巴细胞亚群特征[J]. 标记免疫分析与临床,2022,29(9):1446-1450,1527.
[11] Hudu S A, Shinkafi S H, Umar S, et al. Dynamics of hepatitis B virus surface antigen level with peripheral blood lymphocytes in chronic hepatitis B infection[J]. J Adv Med Med Res, 2020, 32(7): 1-9.
[12] Wang F, Sun W, Xiao Q, et al. Peripheral T lymphocytes predict the severity and prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Medicine, 2021, 100(5):e24075.
[13] 方菊梅, 张万里, 陈怡发, 等. HBV感染型原发性肝癌患者肿瘤微环境中CD4⁺、CD8⁺T细胞和VEGF水平变化特征及其临床意义[J]. 实用癌症杂志,2020,35(5):740-744.
[14] He Y, Cai W, Chen J, et al. Persistent chronic immune activation in HIV/HBV‐coinfected patients after antiretroviral therapy[J]. J Viral Hepat, 2021, 28(10): 1355-1361.
[15] Yan Y, Zhao W, Liu W, et al. CCL19 enhances CD8⁺ T-cell responses and accelerates HBV clearance[J]. J Gastroenterol, 2021, 56: 769-785.
[16] 蒋端凤, 莫秋玉, 林文远, 等. CD4⁺CD25⁺调节性T细胞在HBV感染相关性血小板减少患者外周血中的比例和意义[J]. 中国免疫学杂志,2019,35(20):2522-2526.
[17] Agueguia F S A, Talla P, Assoumou M C O, et al. Involvement of CD95 and ligand in CD4⁺ T-cell and CD8⁺ T-cell depletion and hepatic cytolysis in patients with chronic viral hepatitis B[J]. Afr J Lab Med, 2021, 10(1): 1-6.
[18] EL-Ageery S M. Immune profile of peripheral blood T-lymphocyte subpopulations in chronic hepatitis B[J]. J Med Microbiol, 2021, 30(3): 173-178.
[19] 张亚梅. 生化检验中AST、CHE水平表达在肝硬化患者诊断中应用[J]. 生命科学仪器,2023,21(z1):332.
[20] Cai J, Wu W, Wu J, et al. Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA[J]. Ann Transl Med, 2022, 10(1):25.
[21] Wu J W, Kao J H, Tseng T C. Three heads are better than two: hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma[J]. Clin Mol Hepatol, 2021, 27(4): 524.
[22] Tian Y, Hua W, Wu Y, et al. Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis[J]. Front Immunol, 2021, 12: 745541.